Table 1 Demographic characteristics of study cohorts
Parameters | Total (n = 76) | Mild/Moderate (n = 53) | Severe (n = 23) | Mild/Moderate Vs Severe (p-value) |
|---|---|---|---|---|
Age (y) (median [IQR]) | 39 (30–52) | 38 (29–50) | 42 (30–57) | 0.381 |
Sex-Female (n [%]) | 46 (60.5%) | 33 (62.3%) | 13 (56.5%) | 0.799 |
BMI (kg/m2) (median [IQR]) | 27.8 (23.1–30.9) | 27.9 (23.0–33.8) | 27.0 (23.3–28.7) | 0.354 |
Ethnicity (Caucasian) (n [%}) | 65 (85.5%) | 45 (84.9%) | 20 (87.0%) | 1.000 |
History of smoking (n[%}) | 25 (32.9%) | 15 (28.3%) | 10 (43.5%) | 0.288 |
Current smoking (n[%]) | 5 (6.6%) | 4 (7.5%) | 1 (4.3%) | 1.000 |
FEV1 (% predicted) (median [IQR]) | 86 (71.0–92.7) | 90 (79–97.5) | 65 (53–89) | < 0.001 |
FEV1/FVC (median [IQR]) | 82.5 (69.0–87.7) | 84.0 (73.5–91.0) | 72.0 (57–83) | < 0.001 |
IgE* (kU/L) (median [IQR]) | 1.78 (1.28–2.20) | 1.79 (1.36–2.23) | 1.72 (1.17–2.15) | 0.632 |
CCL5 (ng/ml) | 50 (36.3–77.6) | 42.7 (34.0–64.1) | 71.4 (42.1–83.5) | 0.018 |
PGD2 (pg/ml) | 346 (130–769) | 344 (115–848) | 388 (212–765) | 0.665 |
IL-13 (pg/ml) | 4.47 (1–22.3) | 2.1 (1.0–14.2) | 15.0 (1–42.7) | 0.051 |
Total ICS dose (fluticasone equivalent-µg/day) | 393 (0–1000) | 137 (0–500) | 1000 (1000–1173) | < 0.001 |
Biologics (n[%]) | 6 (7.8%) | 0 (0%) | 6 (26%) | < 0.001 |